|
DUBAI, UAE, Jan. 7, 2026 /PRNewswire/ -- Bybit, the world's second-largest cryptocurrency exchange by trading volume, has revealed the 2025 highlights of Bybit Spot, marking a transformative year for business line. Defined by strategic market positioning that consistently delivered early access to breakout assets before the hype, Bybit Spot proactively identified and listed high-potential tokens ahead of broader discovery, unlocking advanced entry opportunities and a rewarding experience for traders.
First to Market: TRUMP, XAUT, xStocks, TUNA, and MET
Bybit Spot helped users secure first-mover advantages across the year's most significant asset launches. The platform was among the earliest to list TRUMP, the first dynamite memecoin of 2025 that hit an all-time high (ATH) of 548%. In the RWA space, Bybit pioneered CEX trading for XAUT, a gold-backed token that saw an ATH of 127%, and xStocks, enabling on-chain trading capturing the upside of traditional equities, with GOOGLX climbing +107%.
The platform's early discovery approach continued with TUNA, a community-led DeFi token that surged +2,637% on day one, and MET, a liquidity-focused DeFi pick that delivered +255% first-day gains.
Lightning-Fast Listings, High Rewards
Speed to market paired with industry-leading incentives defined Bybit Spot's value proposition. The platform gave away up to $20 million in rewards for select listings including NXPC, an early-stage GameFi breakout, and NIGHT, a privacy-first infrastructure project. By combining early access with substantial reward structures, Bybit transformed market momentum into potential profitability. The strategy propelled Bybit Spot to the No. 1 position in NIGHT's CEX trading market share.
Capturing Diversity in Narratives
Bybit Spot's 2025 lineup spanned the most captivating sectors from celebrity memecoins, AI utilities, to RWA, GameFi, on-chain equities, next-generation Layer 1s, and privacy-first infrastructure. The diversified approach ensured Bybit users' access to multiple market narratives wherever opportunities emerged.
Throughout 2025, Bybit Spot delivered on its promise of an ultra-rewarding trading experience, platforming spotlight projects every month and delivering first-mover advantage at every turn. Looking ahead, 2026 stands to be another year of building momentum and sharing growth.
#Bybit / #CryptoArk / #IMakeIt
About Bybit
Bybit is the world's second-largest cryptocurrency exchange by trading volume, serving a global community of over 80 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.
For more details about Bybit, please visit Bybit Press
For media inquiries, please contact: media@bybit.com
For updates, please follow: Bybit's Communities and Social Media
Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube
DUBAI, UAE, Jan. 7, 2026 /PRNewswire/ -- Bybit, the world's second-largest cryptocurrency exchange by trading volume, has revealed the 2025 highlights of Bybit Spot, marking a transformative year for business line. Defined by strategic market positioning that consistently delivered early access to breakout assets before the hype, Bybit Spot proactively identified and listed high-potential tokens ahead of broader discovery, unlocking advanced entry opportunities and a rewarding experience for traders.
First to Market: TRUMP, XAUT, xStocks, TUNA, and MET
Bybit Spot helped users secure first-mover advantages across the year's most significant asset launches. The platform was among the earliest to list TRUMP, the first dynamite memecoin of 2025 that hit an all-time high (ATH) of 548%. In the RWA space, Bybit pioneered CEX trading for XAUT, a gold-backed token that saw an ATH of 127%, and xStocks, enabling on-chain trading capturing the upside of traditional equities, with GOOGLX climbing +107%.
The platform's early discovery approach continued with TUNA, a community-led DeFi token that surged +2,637% on day one, and MET, a liquidity-focused DeFi pick that delivered +255% first-day gains.
Lightning-Fast Listings, High Rewards
Speed to market paired with industry-leading incentives defined Bybit Spot's value proposition. The platform gave away up to $20 million in rewards for select listings including NXPC, an early-stage GameFi breakout, and NIGHT, a privacy-first infrastructure project. By combining early access with substantial reward structures, Bybit transformed market momentum into potential profitability. The strategy propelled Bybit Spot to the No. 1 position in NIGHT's CEX trading market share.
Capturing Diversity in Narratives
Bybit Spot's 2025 lineup spanned the most captivating sectors from celebrity memecoins, AI utilities, to RWA, GameFi, on-chain equities, next-generation Layer 1s, and privacy-first infrastructure. The diversified approach ensured Bybit users' access to multiple market narratives wherever opportunities emerged.
Throughout 2025, Bybit Spot delivered on its promise of an ultra-rewarding trading experience, platforming spotlight projects every month and delivering first-mover advantage at every turn. Looking ahead, 2026 stands to be another year of building momentum and sharing growth.
#Bybit / #CryptoArk / #IMakeIt
About Bybit
Bybit is the world's second-largest cryptocurrency exchange by trading volume, serving a global community of over 80 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.
For more details about Bybit, please visit Bybit Press
For media inquiries, please contact: media@bybit.com
For updates, please follow: Bybit's Communities and Social Media
Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Bybit Spot 2025 Highlights: Unlocking Early Access to High-Potential Assets
|
HONG KONG, Jan. 9, 2026 /PRNewswire/ -- Ribo Life Science Co., Ltd. ("Ribo" or the "Company", stock code: 06938.HK), a leading company in small interfering RNA (siRNA) therapeutics, today successfully listed on the Main Board of Hong Kong Stock Exchange, marking a significant milestone in the capitalization of Chinese biopharmaceutical enterprises in the siRNA field and injecting new momentum into the industry.
In its global offering, Ribo issued a total of 31,610,400 shares at an offer price of HKD 57.97 per share, raising gross proceeds of over 1.8 billion Hong Kong dollars, HKPO was over 100x oversubscribed, International Placing was 16.7x oversubscribed, reflecting strong global investor confidence in the value of the siRNA sector and the Company's capabilities. The IPO proceeds will provide solid financial support for the advancement of the Company's core business. In addition, the offering attracted 12 cornerstone investors, including Arc Avenue, Ivy Rock, Springs Capital, China Asset Management, Dacheng International and Dacheng Fund, and Taikang Life Insurance etc., demonstrating the strong confidence of leading institutions in the Company's long-term prospects.
Dr. Zicai Liang, Founder, Chairman and Chief Executive Officer of Ribo, commented: "Listing on the Hong Kong Stock Exchange represents a major milestone in Ribo's journey. We extend our sincere gratitude to global investors for their trust and support. Moving forward, we will leverage the international capital markets to accelerate the global clinical development and commercialization of siRNA therapeutics, further strengthen our technologies, deliver breakthrough therapies to patients worldwide while creating sustainable value for shareholders."
Proceeds from the offering will be allocated across four key areas: (1) Advancing global multicenter clinical trials for core products; (2) Supporting preclinical and clinical development of the pipeline; (3) Iterating and upgrading siRNA delivery and other technology platforms; (4) Replenishing operational capital and earmarking funds for routine corporate purposes.
Ribo has built a fully integrated R&D platform with independent intellectual property rights. Its innovative liver-targeting RiboGalSTARTM delivery technology has successfully advanced multiple products into Phase II clinical trials. The Company has established R&D centers in Suzhou, Beijing and Gothenburg, Sweden, and a global R&D network capable of supporting end-to-end drug development from discovery to global clinical trials.
The listing was jointly sponsored by China International Capital Corporation and Citigroup, which provided professional support for the Company's successful entry into the capital markets.
About Ribo Life Science
Suzhou Ribo Life Science Co., Ltd. (06938.HK) is a global biopharmaceutical company engaged in the development and commercialization of small interfering RNA (siRNA) therapeutics. Powered by its proprietary and innovative siRNA technology platforms, the Company has built a rich and differentiated pipeline targeting major disease areas including cardiovascular, metabolic, liver and kidney diseases. Ribo is committed to delivering revolutionary treatment solutions to patients worldwide through continuous innovation.
For more information, please visit: www.ribolia.com.
HONG KONG, Jan. 9, 2026 /PRNewswire/ -- Ribo Life Science Co., Ltd. ("Ribo" or the "Company", stock code: 06938.HK), a leading company in small interfering RNA (siRNA) therapeutics, today successfully listed on the Main Board of Hong Kong Stock Exchange, marking a significant milestone in the capitalization of Chinese biopharmaceutical enterprises in the siRNA field and injecting new momentum into the industry.
In its global offering, Ribo issued a total of 31,610,400 shares at an offer price of HKD 57.97 per share, raising gross proceeds of over 1.8 billion Hong Kong dollars, HKPO was over 100x oversubscribed, International Placing was 16.7x oversubscribed, reflecting strong global investor confidence in the value of the siRNA sector and the Company's capabilities. The IPO proceeds will provide solid financial support for the advancement of the Company's core business. In addition, the offering attracted 12 cornerstone investors, including Arc Avenue, Ivy Rock, Springs Capital, China Asset Management, Dacheng International and Dacheng Fund, and Taikang Life Insurance etc., demonstrating the strong confidence of leading institutions in the Company's long-term prospects.
Dr. Zicai Liang, Founder, Chairman and Chief Executive Officer of Ribo, commented: "Listing on the Hong Kong Stock Exchange represents a major milestone in Ribo's journey. We extend our sincere gratitude to global investors for their trust and support. Moving forward, we will leverage the international capital markets to accelerate the global clinical development and commercialization of siRNA therapeutics, further strengthen our technologies, deliver breakthrough therapies to patients worldwide while creating sustainable value for shareholders."
Proceeds from the offering will be allocated across four key areas: (1) Advancing global multicenter clinical trials for core products; (2) Supporting preclinical and clinical development of the pipeline; (3) Iterating and upgrading siRNA delivery and other technology platforms; (4) Replenishing operational capital and earmarking funds for routine corporate purposes.
Ribo has built a fully integrated R&D platform with independent intellectual property rights. Its innovative liver-targeting RiboGalSTARTM delivery technology has successfully advanced multiple products into Phase II clinical trials. The Company has established R&D centers in Suzhou, Beijing and Gothenburg, Sweden, and a global R&D network capable of supporting end-to-end drug development from discovery to global clinical trials.
The listing was jointly sponsored by China International Capital Corporation and Citigroup, which provided professional support for the Company's successful entry into the capital markets.
About Ribo Life Science
Suzhou Ribo Life Science Co., Ltd. (06938.HK) is a global biopharmaceutical company engaged in the development and commercialization of small interfering RNA (siRNA) therapeutics. Powered by its proprietary and innovative siRNA technology platforms, the Company has built a rich and differentiated pipeline targeting major disease areas including cardiovascular, metabolic, liver and kidney diseases. Ribo is committed to delivering revolutionary treatment solutions to patients worldwide through continuous innovation.
For more information, please visit: www.ribolia.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Ribo Life Science (06938.HK) Successfully Lists on the Main Board of the Hong Kong Stock Exchange
